Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Cytokinetics (Nasdaq: CYTK) announced that company management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026 at 1:30 PM ET.
According to Cytokinetics, the event will be webcast live and the replay will be archived on the company website for 90 days.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – CYTK
On the day this news was published, CYTK gained 0.83%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CYTK rose 0.18% with mixed peer moves: AXSM -1.59%, LEGN +0.84%, ABVX +5.69%, RYTM +0.56%, NUVL +1.53%, suggesting stock-specific factors rather than a uniform sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 18 | Inducement equity grants | Neutral | +1.2% | Inducement stock options and RSUs granted to new employees. |
| Mar 16 | Scientific conference data | Positive | +0.9% | Four ACC 2026 presentations on MYQORZO clinical and ECG analyses. |
| Mar 02 | Investor conferences | Neutral | -1.2% | Participation in multiple March healthcare investor events in Miami Beach. |
| Feb 24 | Earnings & update | Positive | -10.3% | Q4 2025 results, cash position, revenue and 2026 expense guidance. |
| Feb 17 | Regulatory approval | Positive | +0.5% | European Commission approval of MYQORZO for symptomatic oHCM adults. |
Recent company updates, including regulatory and scientific milestones, mostly saw modest positive alignment, with one notable negative reaction to earnings and guidance.
Over the last few months, Cytokinetics announced EC approval of MYQORZO, detailed Q4 2025 financials and 2026 expense guidance, highlighted four ACC 2026 presentations, and disclosed inducement equity grants plus multiple conference appearances. Most of these news items were followed by relatively small moves, while the Q4 2025 earnings and business update on Feb 24 coincided with a larger negative reaction. Today’s conference participation fits the pattern of routine corporate communication.
Market Pulse Summary
This announcement highlights Cytokinetics’ participation in the 25th Annual Needham Virtual Healthcare Conference, with a fireside chat on April 13, 2026 at 1:30 PM ET and a webcast replay available for 90 days. It continues a pattern of active investor outreach following recent MYQORZO regulatory milestones and Q4 2025 financial disclosures. Recent insider filings, including open-market and planned sales, provide additional context on management’s trading activity around these communications.
AI-generated analysis. Not financial advice.
SOUTH SAN FRANCISCO, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 1:30 PM Eastern Time.
Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event.
About Cytokinetics
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Aficamten is also being studied for the potential treatment of non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Disclaimer
Omecamtiv mecarbil and ulacamten are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
